Operating Expenses

R&D

Veradermics R&D increased by 82.8% to $20.93M in Q1 2026 compared to the prior quarter.

Analysis

StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026

How to read this metric

High spending signals a commitment to future growth and innovation, though it reduces current period earnings.

Detailed definition

Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...

Peer comparison

Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.

Metric ID: is_research_and_development

Historical Data

2 periods
 Q1 '25Q1 '26
Value$11.45M$20.93M
QoQ Change+82.8%
YoY Change+82.8%
Range$11.45M$20.93M
Avg YoY Growth+82.8%
Median YoY Growth+82.8%

Business Segments

View all
SegmentQ1 '26
Reportable Segment$17.19M
Total$20.93M

Frequently Asked Questions

What is Veradermics 's r&d?
Veradermics (MANE) reported r&d of $20.93M in Q1 2026.
What does r&d mean?
The money spent on creating new technology and improving existing products.